The French company Ciliatech, specialized in ophthalmology and which is developing a new implant for the treatment of glaucoma, announces today the positive results of the post-operative follow-up at 24 months in the clinical trial evaluating the first generation of its interposition device. cilioscleral (CID – Cilio-scleral Inter-positioning Device).
This new technology differs from other implants used to improve drainage of aqueous humor in the eye, thereby lowering intraocular pressure (IOP) to limit vision loss.
While all existing surgical techniques and implants penetrate the anterior chamber of the eye, the CID advertises itself as “ the very first implant that leaves the anterior chamber completely intact ».
And to specify that he avoids the disadvantages of traditional methods, which can lead to major complications, including blebs (a small bubble of liquid above the surface of the eye or under the eyelid) or loss of endothelial cells corneal ».
According to the results of this study at 24 months, these implants seem to show IOP stability over time, on average around 15 mmHg, i.e. in the safety zone. There is also a significant drop in the use of drugs against glaucoma (-85%) and no treatment failure.
Patient follow-up shows that DIC is safe, with no adverse effects reported since the 12-month follow-up visit.
« The 24-month follow-up results are always an important and highly anticipated milestone for any interventional glaucoma treatment. With 86% of patients still medication-free at 24 months, we are absolutely thrilled with these remarkable CID results, which include very stable IOP and sustained reduction in medication intake post-surgery. », emphasizes Olivier Benoit, CEO of Ciliatech.
This clinical study was carried out in Yerevan, Armenia, under the leadership of Dr. Lilit Voskanyan, ophthalmologist and head of the glaucoma department at the Malayan Center. A cohort of 20 patients was enrolled in the trial in December 2020. Of these, 14 patients were followed up to 24 months.
None of the patients had to undergo additional interventional treatments (laser, surgery, or other). The results obtained are clinically significant, since 78% of patients now have an IOP below 18mmHg and all are below 21mmHg.
Glaucoma is a common disease (80 million people worldwide), especially after 40 years. It is caused by the accumulation of a liquid, the aqueous humor, in the eye. This causes an increase in intraocular pressure (IOP), which damages the optic nerve and leads to loss of vision.
Ciliatech will submit these results for publication in a peer-reviewed journal by the end of 2023.